Autoimmune hepatitis (AIH) is an immune-mediated chronic inflammatory liver disease of unknown etiology characterized by high gamma-globulins, serum autoantibodies, and a predominantly periportal interface hepatitis with lymphoplasmacytic infiltrate on liver histology.
failure, and portal hypertension common in survivors. 6 In contrast, according to existing literature, the 5-year survival of patients with treated AIH is ! 90% and may be similar to that of the general population.
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First-line treatment regimens for AIH include predni(sol) one either alone or in combination with azathioprine.
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Three randomized controlled trials (RCTs) conducted in the 1970s demonstrated that both therapies were effective in achieving remission and reducing liver-related morbidity and mortality. [13] [14] [15] Subsequently, a systematic review of all RCTs of AIH therapies concluded that both predni(sol)one monotherapy and predni(sol)one in combination with azathioprine were equally effective in inducing clinical, biochemical, and histological remission. 16 While efficacy is similar, two-thirds of patients receiving prednisolone therapy experience steroid-related side effects, including cosmetic changes, diabetes, hypertension, cataracts, neuropsychiatric changes, peptic ulceration, and osteoporosis. The incidence of these steroid-related effects is reduced via dose minimization/ titration and/or the use of combination predni(sol)one þ azathioprine. 17 For these reasons, the combination regime is preferable as the first-line treatment. More recently, budesonide in combination with azathioprine has been shown in a multicenter RCT to be as effective as prednisolone plus azathioprine in achieving remission and to have less steroidspecific side effects in patients with AIH without cirrhosis.
to < 2Â ULN (upper limit of normal) in 65% of patients within 18 months and 80% of patients within 3 years. 14, 18, 19 However, around 20% of subjects have a suboptimal treatment outcome either with worsening liver disease despite treatment adherence in 9% of cases or an inability to meet remission criteria in 13%. 20, 21 Moreover, relapse rates are quite common being around 80 to 90% following complete drug withdrawal,
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while around 10% discontinue azathioprine and 13% cease corticosteroids due to drug toxicity and/or intolerance with both physical and psychological side effects impacting the ability of subjects to complete prescribed therapy. [24] [25] [26] For these patients, alternative immunosuppressive therapies are required to induce and/or maintain remission. Over the past decade, several noncorticosteroid-based salvage therapies have been evaluated and incorporated into clinical practice guidelines to facilitate treatment of patients who fail or are intolerant of standard treatment with corticosteroids with/without thiopurine(s). Such immunosuppressive agents include calcineurin inhibitors, mTOR inhibitors, mycophenolate mofetil (MMF), methotrexate, cyclophosphamide, and biological therapies, such as recombinant monoclonal antibodies that target key components of the immune system responsible for liver damage (e.g., rituximab and anti-TNF, ►Table 1). In this report, we critically review the outcomes of salvage treatment strategies that have been tried, to date, for difficult to treat AIH and discuss future therapeutic options, including site-specific targeted therapies in the context of recent advances in the understanding of the immunopathogenesis of the condition.
Immunopathogenesis of AIH
While the immunopathogenesis of AIH is incompletely understood, current opinion is that AIH could develop from an interaction between an environmental trigger(s) and genetic factors in a genetically susceptible host. [27] [28] [29] At a genetic level, susceptibility to AIH is strongly linked to the human leukocyte antigen (HLA) region and in particular DRB1 Ã 0301 and DRB1 Ã 0401 alleles among Europeans and North Americans.
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Potential environmental triggers for AIH include viral infections and medications. There are several classes of medications that have been implicated in inducing an autoimmune-like druginduced-liver injury (DI-AIH). Examples include minocycline, nitrofurantoin, α-methyldopa, fibrates, hydralazine, 5-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins), and tumor necrosis factor-α (TNF-α) antagonists.
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While a detailed discussion of DI-AIH and drug induced liver injury is beyond the scope of this review, it is important to realize that AIH and DI-AIH may share many clinical, histological, and even serological patterns, which can complicate their differentiation, although histological features of chronicity/cirrhosis or relapse after immunosuppressive dose reduction or withdrawal favors a diagnosis of classical AIH rather than DI-AIH.
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Regardless of the trigger, initiation of the autoimmune attack is mediated via the presentation of an autoantigenic peptide within a major histocompatibility complex (MHC) molecule by antigen presenting cells (APCs) to undifferentiated CD4 effector cells. 27, 32 When this occurs in the presence of costimulatory cytokines, including interferon-γ (IFN-γ) and interleukin (IL)-12, naive CD4 helper T cell differentiation is encouraged, which in turn results in IFN-γ secretion. IFN-γ production triggers several effector immune mechanisms, including activation of monocytes and cytotoxic CD8 T-cells and promotion of killing of natural killer (NK) cells. In addition, IFN-γ results in upregulation of MHC class I and induction of aberrant class II expression by hepatocytes that in turn further exacerbate liver injury via further activation of CD4 T cells and antigen presentation to CD8 T cells.
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At the humoral level, exposure to IL-4 stimulates Th2-cell differentiation, which promotes humoral immunity via secretion of several cytokines (IL-4, IL-10, IL-13) that stimulate plasma cell production and the subsequent development of autoantibodies. 27 Current evidence indicates that autoantibody production may contribute to hepatocyte injury via antibodymediated cellular cytotoxicity and complement activation.
28
Regulatory immune mechanisms also appear to be impaired in AIH resulting in an imbalance between regulatory and effector mechanisms and ultimately a breakdown in immune tolerance. 27 In particular, functional deficiencies in the CD4(þ)CD25(þ)CD127(low)FOXP3(þ) regulatory T cells (Tregs) have been described in patients with juvenile-onset AIH, with the frequency of these cells inversely correlating with the markers of disease activity. 34 Such deficient Tregs produce less IL-10 and have reduced ability to suppress CD4 target cells. In addition, when exposed to proinflammatory stimuli, Tregs in AIH appear to be more susceptible to exhibit effector cell-like behavior via enhanced production of IFN-γ and IL-17 35 ; this in turn may exacerbate liver injury.
Treatment Endpoints
The main objective of treatment of AIH is to achieve remission of disease that is defined as the complete biochemical and histological resolution of activity based, respectively, on normalization of serum aminotransferase, serum bilirubin, and gamma-globulin levels and the absence of interface hepatitis on liver biopsy. [10] [11] [12] Those who show some or no improvement in clinical, laboratory, and histological features over 2 to 3 years of continuous therapy despite treatment compliance are deemed to have an incomplete response,
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although the majority have marked improvements in indices of activity occurring within the first 3 to 6 months. 11, 12 This is distinct from treatment failure, which is defined as the worsening of clinical, laboratory, and histological features in subjects on standard treatment including development of liver decompensation. with therapy also impacts patient outcomes with nonadherence to treatment during follow-up associated with a high relapse rate and liver failure. 43 Pediatric patients entering puberty and adolescents are particularly at risk of poor compliance, 43, 44 and hence this population should receive additional support, motivation, and encouragement to achieve an optimal treatment response.
Early Identification of Poor Responders
It is important to identify early those patients who respond poorly to standard therapy, as they will require an alternative treatment strategy to induce remission. An estimated 13% of patients fail to enter remission after 36 months of treatment, and hence are classified as incomplete responders. The initial management of subjects with treatment failure on standard therapy is greatly dependent on the severity of the underlying liver disease. In those without liver failure, current recommendations are to treat patients with high-dose prednisolone 30 to 60 mg/day orally with azathioprine 150 mg/day or 2 mg/kg/day (if no cytopenias) for up to 4 weeks (►Table 1, ►Fig. 1). [10] [11] [12] In addition, hospital admission should be considered initially for intravenous steroids (e.g., methylprednisolone 100 mg/day), particularly if treatment compliance is questionable. 12 Following the initial 4-week induction period, the steroid dose should be reduced by 10 mg/month and then stabilized on a dose of 20 mg/day (►Fig. 1). [10] [11] [12] The evidence, however, for such recommendations is relatively weak and of low quality being mainly derived from expert opinion and a single case series. 50, 51 In poor responders, with severe liver disease, including those with an acute fulminant presentation, patient management should be in conjunction with a liver transplant center. There is limited evidence that such patients benefit from a course of high-dose predni(sol)one (! 1 mg/kg) intravenously.
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Budesonide Budesonide, a potent second-generation corticosteroid, with high first-pass metabolism in the liver following oral ingestion, is an effective first-line therapy for AIH but is considered to be relatively ineffective in steroid nonresponders because of its similar mode of action. 53 It may, however, be useful in noncirrhotic subjects who are intolerant to standard therapy because of steroid-specific side effects. 53 In a small series of 13 patients with relapsed AIH, 11 of whom were intolerant to steroids, treatment with budesonide in a dose of 6 to 8 mg/day for the first 6 to 10 weeks improved serum ALT and immunoglobulin levels without causing significant steroid side effects. 54 In comparison, in a pilot study of 10 patients with steroid-dependent disease, budesonide 9 mg/day was unable to control disease activity in the majority of patients with 7 developing worsening disease and/or treatment intolerance. 55 Still, results
are not uniform with another study that showed budesonide 3 to 9 mg/day to suppress disease activity in seven of nine patients with steroid-dependent or refractory disease without causing major side effects. 56 Similarly, in another open-label pilot study involving 18 patients treated with budesonide 9 mg/day for up to 24 weeks, all 8 patients who received treatment for steroid refractory AIH achieved remission.
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Data are limited, however, on the ability of budesonide to achieve a durable response and/or histological remission when used in such settings.
Deflazacort
Deflazacort is an oxazoline derivative of prednisolone that has both immunosuppressive and anti-inflammatory properties. 58 It is considered more attractive to use in subjects with or at risk of steroid intolerance, as it has fewer side effects than prednisolone at equivalent doses. 59 Thus far, the limited number of studies conducted with this agent have mostly focused on its role as maintenance therapy for AIH.
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In one open-label study of 15 patients, who were in remission on maintenance prednisolone, conversion to deflazacort 7.5 mg/day did not lead to biochemical deterioration or deleterious side effects. 60 Nevertheless, like budesonide, it is unlikely to be effective as a salvage therapy for those with a poor or nonresponse to prednisolone, given that it acts via the same glucocorticoid receptor.
Azathioprine-Based Regimens
Azathioprine is a purine analogue that interferes with DNA synthesis and is particularly applicable to rapidly proliferating cells such as lymphocytes. Around 10% of subjects will have a suboptimal response to combination therapy due to a lack of therapeutic effect or intolerance to azathioprine. 10, 12 In this context, azathioprine is converted nonenzymatically to 6-mercaptopurine but achieves maximal effectiveness as an immunosuppressive agent via subsequent enzymatic conversion by hypoxanthine phosphoribosyltransferase to its pharmacologically active metabolite, 6-tioguanine(thioguanine) nucleotides (6-TGN, ►Fig. 2). However, 6-mercaptopurine also undergoes enzymatic conversion by xanthine oxidase to the hepatotoxic thiopurine metabolite, 6-methylmercaptopurine (6-MMP), which in some patients may be preferentially generated (►Fig. 2). 61, 62 Thiopurine methyltransferase (TPMT) is the enzyme central to this metabolic process with the activity of TPMT determining the degree to which methylated breakdown products such as 6-MMP are produced (►Fig. 2). As TPMT activity is known to vary among individuals likely because of differing TPMT phenotypes, 63 so the levels of 6-TGN and 6-MMP.
Experience from the literature on inflammatory bowel disease has shown that the generation of high levels of 6-MMP at the expense of 6-TGN is associated with azathioprine hepatotoxicity and an inadequate therapeutic response to azathioprine.
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Conversely, achieving higher concentrations of 6-TGN is associated with the development of remission in AIH. 65 ►Table 2 outlines the potential utility of azathioprine metabolites in AIH in relation to monitoring for compliance, efficacy, and toxicity. However, further studies are needed to clarify the appropriate use of 6-TGN and 6-MMP metabolite testing in dose titration and treatment optimization. Still, TMPT activity and azathioprine metabolites testing could be considered in patients with a suboptimal response to standard therapy, as the results can assist in identifying patients with poor compliance (i.e., low 6-MMP, low 6-TGN). Furthermore, baseline TPMT testing may help identify patients at higher risk of developing azathioprine toxicity and therefore identify a cohort of patients more suitable for alternate treatment regimens (►Table 2). In this algorithm, we have included current recommendations for salvage therapy [10] [11] [12] to manage refractory/recalcitrant disease, including the off-label empirical use of the calcineurin inhibitors, cyclosporine and tacrolimus, and mycophenolate mofetil that are based mostly on several single center observational cohort data and not on randomized controlled trials.
Allopurinol
The concomitant use of the xanthine oxidase inhibitor, allopurinol with low-dose thiopurine causes a preferential increase in 6-TGN production and reduction in 6-MMP formation (►Fig. 2). Such an approach has been successfully adopted in patients with inflammatory bowel disease to optimize 6-TGN levels in thiopurine nonresponders. 66, 67 This treatment strategy was also reported to be successful in a small case series of patients with AIH with nonresponse or intolerance to thiopurines. 68, 69 In an open-label trial, allopurinol 100 mg/day was coadministered with thiopurine at 25 to 33% of the original dose in eight patients with AIH and unfavorable thiopurine metabolism and intolerance to or inadequate response to conventional thiopurines. All subjects showed improved liver chemistries, with sustained biochemical improvement seen in seven, associated with a significant increase in 6-TGN levels.
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While this approach has sound rationale and appears to be safe and simple, more objective data are needed before recommending it to be widely adopted.
Noncorticosteroid-Based Immunosuppressive Regimens

Calcineurin Inhibitors
Cyclosporine and tacrolimus are both calcineurin inhibitors (CIs) that intervene with the T lymphocyte-mediated response via interference with lymphocyte proliferation. 70 Despite extensive experience with the use of these medications in the organ transplant setting, there are only small and predominantly nonrandomized trials to support their use in AIH. Coupled with the potential for serious adverse effects and the requirement for frequent drug monitoring, both cyclosporine and tacrolimus are employed less frequently than MMF as the second-line therapy, 71 usually being reserved for a more selective group of patients (►Fig. 1).
Cyclosporine
Cyclosporine is a lipophilic cyclic peptide that binds with high affinity to a family of cytoplasmic proteins called cyclophilins.
The resultant complex competitively binds and inhibits calcineurin, which is a phosphatase that activates nuclear factors.
Immunosuppressive effect of cyclosporins stems from the inhibition of the translocation of a family of transcription factors (NF-AT) that in turn inhibits IL-2, the proinflammatory cytokine, thereby inhibiting lymphocyte proliferation.
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A limited number of studies have explored the use of cyclosporine as the first-line [72] [73] [74] [75] [76] and/or second-line therapy in steroid-refractory or intolerant patients [75] [76] [77] [78] [79] [80] [81] [82] (►Table 3).
Malekzadeh published the results of an open-label study of cyclosporine in a population of treatment naive (n ¼ 9) and steroid refractory (n ¼ 10) subjects. 75 Dosing was 2 to 5 mg/kg/day in divided doses and then titrated to a trough level of 100 to 300 ng/mL. Patients were treated for 26 weeks, although only 15 completed therapy due to nonresponse and/ or side effects. Overall, there was a significant improvement in serum ALT levels from 455 to 79 IU/L, while the mean histologic activity index decreased from 15.2 to 7.1 (p < 0.005). However, side effects were common, including a nonsignificant increase in serum creatinine, hypertension, ALT flare, and diarrhea. 75 The efficacy of cyclosporine in both treatment-naive and treatmentexperienced pediatric patients was explored in two studies, 74, 76 including a prospective pilot study of 32 children (median age: 10 years) with AIH. In this study, 24 of the 30 children completing the 6-month study were able to achieve a reduction in ALT to < 2Â ULN. 74 A small randomized trial compared cyclosporine (2 mg/kg/day) to prednisolone (50 mg/day) as the first-line therapy for AIH. 73 Comparable efficacy was observed between the two treatment groups with biochemical remission rates at 48 weeks being 47 and 50%, respectively. Collectively, there is low-level evidence for the use of cyclosporine in AIH, given the small number of studies, small sample size, and heterogeneity in the patient populations and dosing schedules; these make it difficult to extrapolate the data to individual circumstances. Nevertheless, the limited data available clearly suggest cyclosporine to be efficacious, although its use as a salvage therapy must be carefully balanced against the potential toxicities, including hypertension, renal dysfunction, hyperlipidemia, pancreatitis, neurotoxicity, hirsutism, published an early experience of tacrolimus in 21 patients. Dosing was commenced at 0.075 mg/kg in divided doses and incremented to achieve a trough level of 0.6 to 1.0 ng/mL. Significant improvement in hepatic necroinflammation was noted, although renal dysfunction was observed. Subsequently, several, mostly small, retrospective case series have established a role of tacrolimus as salvage therapy in AIH, particularly in patients who are nonresponders/partial responders or intolerant of steroid-based therapy. [86] [87] [88] [89] [90] In this setting, tacrolimus is generally well tolerated and effective with some evidence suggesting it to be at least as effective as MMF and potentially more efficacious in those with an incomplete response to prednisolone and azathioprine.
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Monitoring drug levels is required with the schedule of dosing and monitoring of tacrolimus essentially derived from experience in the posttransplant setting rather than via clinical studies on AIH. In recent times, tacrolimus has generally been preferred to cyclosporine by transplant centers, and as a consequence, it has become the preferred calcineurin inhibitor as salvage therapy, although no comparative data are available to support this practice. In a review of the literature that included a total of 113 subjects, 84 two-thirds achieved a biochemical response to tacrolimus at a dose between 1 and 6 mg/day. A recent report 87 of 80 patients collected from 19 centers indicated response rates of over 90% when used as a salvage therapy for steroid/azathioprine intolerance but only 56% if tacrolimus was used due to a failure of standard therapy. Overall, 12.5% required treatment withdrawal due to side effects. Further studies are needed to define the efficacy of tacrolimus in comparison to other regimens, although based on current literature and experience, it remains a viable salvage treatment option in steroid-refractory or intolerant patients.
As with cyclosporine, tacrolimus has the potential to cause significant drug toxicity. The most frequent side effects reported are gastrointestinal, such as anorexia, nausea, and diarrhea. However, nephrotoxicity, hypertension, neurotoxicity (tremors, headaches), and diabetes mellitus can also occur and should be monitored for.
Mycophenolate Mofetil
Mycophenolate mofetil (MMF), the morpholinoethyl ester prodrug of mycophenolic acid, undergoes rapid conversion to mycophenolic acid following oral absorption. 91 Like azathioprine, MMF is a purine antagonist that blocks de novo DNA synthesis; however, in contrast to azathioprine, its immunosuppressive properties are independent of the thiopurine methyltransferase pathway of catabolism. 91 MMF has a selective inhibitory effect on both B and T lymphocyte proliferation via potent inhibition of the activity of the type II isoform of inosine-5'-mono-phosphate dehydrogenase; this enzyme is involved in guanosine synthesis in lymphocytes. MMF is a more powerful and better-tolerated agent than azathioprine 92 and is now a regular component of standard therapy for autoimmune diseases 92 and one of the more commonly used salvage therapies for AIH.
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In the absence of randomized controlled trials, data on the efficacy and safety of MMF as salvage therapy in AIH have been derived from several small retrospective, mostly single case series of patients with azathioprine intolerance and/or steroidrefractory disease (►Table 4). 45, [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] Overall response rates in this setting have been between 30 and 84% with a subsequent analyses of four of these studies estimating the biochemical response achieved with MMF to be around 45%.
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The significant variability in response rates likely reflects several key differences between studies, including heterogeneity in study populations and lack of uniformity in the definitions used to codify response. Several small studies evaluating MMF as the salvage therapy suggest that biochemical improvement is significantly more common in patients treated for azathioprine intolerance compared with those treated for corticosteroid and/ or azathioprine-refractory disease. ; two of these studies also reported response rates that did not differ according to treatment indication. 108, 109 However, the uncontrolled nature of studies to date and lack of uniformity in both 14 (39) 2 (25) 12 (43) 11 (31) 4 (11) Aw et al (89) 1 (4.8)
(4.8)
Baven-Pronk et al (38) 16 (70) 15 (33) 6 (13) Park et al (57) 39 of 63 (62) 27 (25) 10 ( The initial dose of MMF in studies has been 0.5 to 1.0 g/day, while doses of 1.0 to 2.0 g/day have been commonly used to induce remission. However, in two studies, a dose of up to 3.0 g/day was used during induction therapy.
98,101 Thereafter, doses of 0.5 to 1.0 g/day were used to maintain remission usually in combination with steroids.
95-103,109
MMF treatment of AIH is generally safe and well tolerated including in those with cirrhosis and prior azathioprine intolerance. 111 Significant side effects occur in 12 to 34% of patients with the majority of these involving the gastrointestinal tract, particularly nausea, vomiting, and diarrhea. Less common side effects include cytopenias, headaches, pancreatitis, neuropsychiatric symptoms, and dermatological reactions. 
mTOR Inhibitors
Sirolimus
Sirolimus or rapamycin is an inhibitor of the mammalian target of rapamycin (mTOR), a regulatory protein that is intimately involved in the proliferation and survival of lymphocytes activated by antigen-stimulated binding of IL-2 to its T-cell receptor (CD25). 110, 112, 113 Sirolimus exerts several immunomodulatory effects that include a potent reduction in the number of proliferating reactive CD4þ and CD8þ (cytotoxic) effector T cells via induction of cytotoxic T cell apoptosis, as well as impairment in the production of key proteins linked toT cellmediated cytotoxicity including perforin and granzyme B.
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This results in a selective expansion in the pool of regulatory (CD4þ CD25 þ) T cells that are innately resistant to the apoptotic effects of rapamycin, and play a key role in suppressing the proliferation and activity of cytotoxic T cells. 114 The beneficial effect of sirolimus on the selective survival of Treg population is modulated by IL-2. 115 This has prompted speculation about the potential benefit of combining calcineurin inhibitors that block IL-2 production with sirolimus, although this has not been formally evaluated in refractory AIH.
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Sirolimus and everolimus have nephroprotective effects and are therefore frequently used in the liver transplant setting, particularly in patients with renal insufficiency posttransplantation and in those with CI-induced nephrotoxicity.
Data on the efficacy and safety of sirolimus as salvage therapy in patients with steroid-refractory AIH are even more sparse than that for MMF being limited to just a few very small case series (Table 1) . [117] [118] [119] In the initial report, Kerkar et al reported their experience of the outcomes of sirolimus in six patients with either de novo or recurrent AIH postliver transplant of whom five were nonresponsive to conventional treatment with prednisolone and azathioprine. 117 All patients responded to the addition of sirolimus with significant reduction in serum ALT levels, histology (when available), and immunoglobulin G (IgG) levels. The doses used were 1.0 to 3.0 mg/day and minimal side effects were noted, although the drug was withdrawn in one patient with severe colitis. 117 In another small single center study, five adult subjects with disease, refractory to prednisolone and azathioprine or MMF, received sirolimus in an initial dose of 2 mg/day. 118 Significant biochemical improvement with > 50% reduction in serum ALT levels was achieved in four (80%) patients with two (40%) achieving a sustained normalization of serum liver enzymes. All patients had a significant reduction in their steroid dose. 118 Side effects were minimal apart from a rise in serum lipids in two patients. Less-positive results were reported in a small study of four pediatric patients with refractory AIH where sirolimus 1.0 to 2.0 mg/m 2 /day led to improvement in serum liver enzymes and/or steroid dose in only two patients.
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Sirolimus has an acceptable safety profile and is generally well tolerated with the main side effects being respiratory in nature, involving cough, dyspnea, and fever. The overall risk of pulmonary toxicity with interstitial pneumonitis from the transplant literature is 2 to 7%, and this is an indication for immediate cessation of mTOR inhibitors. 120, 121 Other reported side effects include hyperlipidemia, fatigue, bone marrow suppression, skin rash, stomatitis, and edema.
Everolimus
Only one small study has evaluated everolimus as the secondline therapy for refractory AIH. 122 Ytting et al reported on seven adults with nonresponse to standard therapy and empirical treatment with MMF, budesonide, and CIs. Treatment with everolimus in an initial dose of 0.75 to 1.5 mg bid led to rapid and significant biochemical improvement by 2 weeks in four subjects. Overall, four subjects achieved sustained biochemical remission and no worsening or improvement in liver fibrosis, while all patients achieved clinical remission within 5 months. 122 Significant reductions in steroid dose were achieved in six patients. Side effects reported include arthralgias, asthma-like symptoms, and 
Cyclophosphamide
Cyclophosphamide in lower doses is an immunosuppressant and has been used as such for the treatment of several immunemediated diseases including vasculitis. Successful induction and long-term maintenance of remission have been reported in three subjects with AIH treated with the combination of cyclophosphamide 1.0 to 1.5 mg/kg and a tapering dose of corticosteroids commencing with 1 mg/kg. 135 No significant side effects were observed over a cumulative observation period of over 12 years. However, the subsequent report that cyclophosphamide can activate the immune system by suppressing Treg function 136 has dampened the enthusiasm for its use as an alternative therapy for AIH.
Biological Therapies
Infliximab
The use of anti-TNF-α therapies, such as infliximab, in AIH is based upon the recognition of the important role TNF-α plays in the cytotoxic T cell immune response including the proliferation and differentiation of lymphocytes. In addition, there are inconsistent reports of a relationship between genetic polymorphisms in the TNF-α promoter region and type 1 AIH. 137 Furthermore, there is considerable experience in the use of biological agents in the treatment and management of other autoimmune conditions, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Despite the biological plausibility of an effect, the use of agents such as infliximab in AIH is quite limited and hence it is not possible to draw any conclusions regarding the potential utility of these therapies in AIH. Infliximab was used in a small trial of 11 treatment-resistant patients 138 using a dose schedule derived from the literature on inflammatory bowel disease (5 mg/kg body weight at time zero, 2 weeks, 6 weeks, and then every 4-8 weeks). Normalization of ALT was recorded in 8 of 11 participants, although 7 subjects developed treatment-related toxicities, predominantly involving opportunistic infections (►Table 1). To further complicate matters, anti-TNF-α antibodies have been associated with the induction of an immune-mediated liver disease resembling AIH. 139 Considering the limited evidence available, the use of anti-TNF-α therapies outside of expert centers cannot be recommended until new efficacy and safety data emerge that support their use.
Rituximab
Rituximab is a chimeric mouse-human monoclonal antibody that promotes depletion of B lymphocytes via binding to the CD20 antigen expressed on the surface of B cells. This binding results in complement and antibody-dependent cellular cytotoxicity, and the resultant B cell depletion has implications for autoantibody formation and interference with both the B and T cell responses. The literature surrounding rituximab use in AIH has predominantly been case reports, with the largest published experience involving six cases that received two infusions of rituximab (1,000 mg) 2 weeks apart in patients refractory to prednisolone plus azathioprine. 140 Biochemical response was observed in all subjects by week 12 and prednisolone was withdrawn in three subjects. The lack of robust clinical data, coupled with concerns regarding the reactivation of latent infections, such as hepatitis B and other potential drug toxicities, means that rituximab cannot be recommended for use in AIH outside highly specialized treatment centers with experience in its use.
Nonimmunosuppressive Therapies
Ursodeoxycholic Acid
Ursodeoxycholic acid (UDCA), an epimer of chenodeoxycholic acid, has several putative therapeutic properties relevant to treating liver diseases that include hepatocytoprotection and immunomodulation. 141 The immunomodulatory actions of UDCA include alterations in class I and II HLA antigen expression on hepatocytes, 142 reduction and/or inhibition of immunoglobulin 143 and cytokine (IL-2, IL-4, and IFN-γ) production,
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stimulation of lymphocyte function, 144 and inhibition of apoptosis. 145 These actions could potentially alter the immune response and reduce hepatocellular injury in AIH. While UDCA is the standard of care for treating primary biliary cholangitis, only a few studies have explored its therapeutic role in AIH. [146] [147] [148] Following the original pilot study that demonstrated UDCA to be efficacious in treatment-naive type 1 AIH subjects, 146 a randomized placebo controlled trial of UDCA (13-15 mg/kg daily) was conducted as salvage therapy in 37 subjects with suboptimal responses to standard therapy.
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Adjunctive therapy with UDCA led to significant biochemical improvement compared with those receiving placebo, although no difference was observed in the need for corticosteroids or rates of clinical improvement and histological response.
Thus, in the absence of further evidence, UDCA cannot be recommended as a salvage therapy for AIH. However, it may still play a potentially important role in those with AIH overlap syndromes where significant cholestatic features exist.
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Plasmapheresis
Plasmapheresis removes semiselectively several large molecules pertinent to immune-mediated tissue damage, including immunoglobulins, autoantibodies, immune complexes, adhesion molecules, and cytokines. 149 The technique has been employed in several different conditions in which humoral factors are implicated in the pathogenesis of disease. 149 While considered potentially useful for the treatment of refractory autoimmune diseases, there have been only four case reports of its use in nonresponsive AIH. [150] [151] [152] [153] Three of these arose in the setting of overlap with other (auto)immune diseases, [150] [151] [152] while the fourth involved a severe case of de novo AIH postliver transplant that was refractory to steroids, MMF, and CIs.
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Institution of plasmapheresis led to remission in the latter case, but maintenance treatment was required to prevent relapse.
Liver Transplantation
Liver transplantation is an important salvage therapy for AIH,
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particularly for severe acute or fulminant cases that are less responsive to corticosteroid therapy. 46, 49, 148 Indeed, in one study of 16 cases of acute fulminant AIH, only 1 of 12 patients treated with corticosteroids improved with 13 needing transplantation. 154 The principal indications for transplantation for AIH are fulminant liver failure from severe acute AIH (nonresponsive to steroids), decompensated cirrhosis, and hepatocellular carcinoma. 155 Patient survival at 5 and 10 years following transplant is excellent being > 80 and > 75%, respectively, while 5-year graft survival is around 75%. [156] [157] [158] Despite posttransplant immunosuppression and the absence of planned HLA donor-recipient matching, AIH recurs in the donor liver in a frequency that is quite variable but generally time dependent; around 12% of patients are affected at 1 year and up to 36% by 5 years. [159] [160] [161] [162] [163] A systematic review of available literature estimated the weighted recurrence of AIH posttransplant at 22%. 164 Factors predictive of recurrence include the severity of hepatic inflammation and level of serum IgG elevation at the time of transplant and coexistent inflammatory bowel disease. 164, 165 Furthermore, most transplant centers include prednisolone in the immunosuppressive regimen of patients transplanted for AIH. Liver histology, including a prominent plasma cell infiltrate with interface hepatitis, may be the only indicator of recurrent disease, 166 although it may be difficult to make this distinction. However, progression to cirrhosis, graft dysfunction, and graft loss appears rare.
159,162,164
Recurrent AIH usually responds well to increased immunosuppression with reintroduction or a higher dose of corticosteroids and/or optimization of CI dosing. 155, 167, 168 However, in refractory cases, sirolimus 117 or azathioprine may be required.
Emerging Salvage Therapies
There is a significant unmet need for novel salvage therapies for AIH that selectively target key components of the immune system involved in the immunopathogenesis of AIH rather than induce blanket immunosuppression. 
Recombinant Interleukin-10
Recombinant interleukin-10 (IL-10) can potentially enhance the anti-inflammatory effects of the type 2 cytokine response and blunt the type 1 cytokine response responsible for the proliferation and differentiation of cytotoxic T cells targeting the liver. 189, 190 Animal and human studies of recombinant IL-10 in liver and nonliver diseases provide a sound rationale for its use in autoimmune liver disease. [191] [192] [193] [194] [195] [196] [197] While administration of recombinant IL-10 reduces liver inflammation and fibrosis in mouse models 197 and in patients with chronic hepatitis C, [193] [194] [195] its side-effect profile, which is similar to interferon, is likely to limit patient acceptability.
196-198
Preimplantation Factor
Secreted by embryos, preimplantation factor (PIF) is a novel biologic immune modulator that is responsible for maternal 
Anti-CD3 Antibody
Immunosuppressive, nonmitogenic CD3 antibodies target the T cell antigen receptor, thereby inducing apoptosis of cytotoxic T cells. 201 The phagocytosis of these apoptotic cells by macrophages and dendritic cells results in the release of transforming growth factor-β (TGF-β), which stimulates the expansion and activity of Tregs [201] [202] [203] [204] ; this in turn facilitates immune tolerance. Preliminary studies in patients with type 1 diabetes show that administration of nonmitogenic CD3 antibodies is generally well tolerated and can improve indices of glucose homeostasis and insulin requirements. [205] [206] [207] Side effects associated with the use of anti-CD3 antibodies include fever, rash, and anemia. Still, it remains to be seen whether this treatment has sufficient safety, specificity, and durability to be a feasible salvage therapy for autoimmune hepatitis.
B Cell-Activating Factor
B cell-activating factor (BAFF) is a member of the TNF superfamily and is influential in the development, maturation, and survival of peripheral B cells that play an integral role in the humoral immune response. These recommendations are based predominantly on level III/IV evidence collected from single center observational studies and expert opinion with no significant randomized controlled trials of salvage therapies having been conducted in this setting. Included among these is the strong recommendation that poor compliance with treatment needs to be excluded, particularly in young patients before alternative treatment strategies are considered for nonresponders to conventional treatment. The accuracy of the diagnosis also needs to be reevaluated, including consideration to repeat liver biopsy, as the poor response to steroids may be due to an alternative diagnosis and/or the coexistence of other conditions, such as chronic hepatitis C, nonalcoholic fatty liver disease, autoimmune cholestatic liver disease, Wilson's disease, α1-antitrypsin deficiency, and hemochromatosis. The initial treatment for those with recalcitrant AIH, associated with significant acute deterioration, is highdose prednisolone monotherapy 60 to 100 mg/day orally or IV. [10] [11] [12] 211, 212 For subjects with a more subacute course of deteriorating liver chemistries and/or liver histology, prednisolone in a lower dose of 30 mg/day combined with high-dose azathioprine (150 mg/day or 2 mg/kg/day) for up to 4 weeks is preferred (►Fig. 1). [10] [11] [12] 211, 212 Responders to this higher dose regimen should then have steroid and azathioprine doses reduced at monthly intervals until reaching maintenance dose levels. Subjects who show evidence of treatment failure and/or progressive liver failure despite treatment should be managed in conjunction with a liver transplant center and undergo evaluation for liver transplantation. Those who fail to respond to first-line salvage therapy and have less severe disease, who are otherwise not suitable for transplantation, should be considered for alternative immunosuppressive therapy. Steroidsparing calcineurin inhibitors are preferred in this setting with tacrolimus as the generally preferred agent over cyclosporine because of its higher potency and larger experience in organ transplantation. 213 Commencement of mycophenolate should also be considered, particularly in those with azathioprine intolerance but also for suboptimal responders to standard therapy, as remission rates up to 60% have been reported when used as rescue therapy. [86] [87] [88] 93 Beyond these, there are limited data to recommend other immunosuppressive agents, including sirolimus, rituximab, and infliximab, as salvage therapies with use of these investigational agents best managed by specialized centers with expertise in managing this condition.
Conclusion
Several agents have been studied as front-line salvage therapy for patients with AIH, who respond suboptimally to conventional therapy, with the more promising of these being calcineurin inhibitors and MMF. However, none of these salvage therapies have undergone rigorous clinical evaluation via randomized clinical trials, with efficacy and safety data thus far being generated predominantly from single or multicenter, mostly retrospective observational cohort studies. There remains much to learn about the utility of these alternative therapies for AIH, including the appropriate timing, dosing, and therapeutic monitoring, following their introduction and the patient population to whom these should be directed. 
Main Concepts and Learning Points
Major concept Learning point
• Around 20% of patients with autoimmune hepatitis fail to respond to conventional therapy
• Patients with refractory or recalcitrant autoimmune hepatitis require salvage therapy
• The optimal salvage treatment strategy for autoimmune hepatitis is unclear
• Several potential salvage therapies have been identified, including calcineurin inhibitors, mycophenolate, and rituximab, but none have undergone rigorous clinical evaluation
• The first-line salvage strategy involves high-dose prednisolone monotherapy AE azathioprine
• Subjects with progressive liver failure should be discussed with a liver transplant center and evaluated for liver transplantation
• Second-line salvage therapy is typically with calcineurin inhibitors (i.e., cyclosporine, tacrolimus) and mycophenolate
• Tacrolimus is generally preferred over cyclosporine and is given in low dose with therapeutic monitoring required • Mycophenolate is effective when used in patients with azathioprine intolerance and to a lesser extent in those with steroid-refractory disease
